STIPE Therapeutics ApS Financials, key figures and credit report
Gross profit - 842.3 kEUR FY 2024 +75.6% vs 2023
EBIT -1 499.8 kEUR FY 2024 +69.7% vs 2023
Net debt -1 123.7 kEUR FY 2024 -139.6% vs 2023
Quick ratio 31.1 FY 2024 +25.4 vs 2023
Income statement (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Fiscal period length | 12 | 12 | 12 | 12 | 12 |
| Net sales | |||||
| Gross profit | -2 948.72 | -4 086.58 | -6 617.05 | -3 456.56 | - 842.28 |
| Employee benefit expenses | -1 608.16 | -1 990.63 | -2 191.79 | -1 501.01 | - 657.48 |
| EBIT | -4 556.88 | -6 077.21 | -8 808.83 | -4 957.57 | -1 499.76 |
| Other financial income | 9.59 | 3.50 | 35.30 | 42.14 | 3 239.59 |
| Other financial expenses | -56.65 | - 147.97 | - 235.53 | - 267.61 | - 291.08 |
| Net income from associates (fin.) | -9.37 | ||||
| Pre-tax profit | -4 603.94 | -6 221.68 | -9 009.07 | -5 192.41 | 1 448.75 |
| Income taxes | 736.28 | 736.28 | 736.28 | 736.28 | |
| Net earnings | -3 867.65 | -5 485.39 | -8 272.78 | -4 456.13 | 1 448.75 |
Assets (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Intangible assets total | |||||
| Tangible assets total | |||||
| Investments total | |||||
| Long term receivables total | |||||
| Inventories total | |||||
| Prepayments and accrued income | 25.35 | ||||
| Current other receivables | 140.50 | 8 157.75 | 146.45 | 146.80 | |
| Current deferred tax assets | 938.49 | 736.28 | 736.28 | 736.28 | |
| Short term receivables total | 1 078.99 | 8 894.04 | 882.74 | 908.43 | |
| Cash and bank deposits | 3 545.95 | 5 617.44 | 5 319.09 | 2 309.18 | 1 123.66 |
| Cash and cash equivalents | 3 545.95 | 5 617.44 | 5 319.09 | 2 309.18 | 1 123.66 |
| Balance sheet total (assets) | 4 624.93 | 14 511.48 | 6 201.83 | 3 217.61 | 1 123.66 |
Equity and liabilities (kEUR)
2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Share capital | 17.19 | 32.06 | 32.06 | 32.06 | 34.72 |
| Other reserves | 7 971.18 | ||||
| Retained earnings | 7 614.88 | 7 714.03 | 10 199.83 | 1 927.04 | - 395.95 |
| Profit of the financial year | -3 867.65 | -5 485.39 | -8 272.78 | -4 456.13 | 1 448.75 |
| Shareholders equity total | 3 764.41 | 10 231.89 | 1 959.11 | -2 497.02 | 1 087.51 |
| Non-current loans from credit institutions | 2 758.64 | 2 906.17 | 5 150.03 | ||
| Non-current other liabilities | 110.37 | ||||
| Non-current liabilities total | 110.37 | 2 758.64 | 2 906.17 | 5 150.03 | |
| Current trade creditors | 513.40 | 1 430.78 | 1 041.30 | 490.73 | 34.86 |
| Other non-interest bearing current liabilities | 236.75 | 90.17 | 295.25 | 73.88 | 1.28 |
| Current liabilities total | 750.16 | 1 520.96 | 1 336.55 | 564.61 | 36.15 |
| Balance sheet total (liabilities) | 4 624.93 | 14 511.48 | 6 201.83 | 3 217.61 | 1 123.66 |
Secure checkout
Buy AI Credit Risk Report
Pay by card and the report is generated automatically and sent to your email. One-time payment – no subscription.
How it works
- 01 You pay €3 (incl. VAT) securely by card via Stripe.
- 02 You enter your email address in Stripe's payment window – the report is sent there.
- 03 The report is generated automatically and sent as a PDF within 30 minutes.
- 04 If generation should fail, you are not charged.
- 05 You receive the receipt by email once the report has been generated and completed.
Do you want to buy the AI Credit Risk Report (3 EUR / report)?
The report is sent to the email address you enter in Stripe's payment window. Please also check your spam folder. Questions? Write to info@creditreports.dk.
Page generated